Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.17 USD | -4.56% | -3.88% | -20.76% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
End-of-day quotes
Sector Other Advanced Medical Equipment & Technology
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
235M | - | |||||
227B | ||||||
197B | ||||||
141B | ||||||
110B | ||||||
64.15B |
- Stock Market
- Equities
- NPCE Stock
- Charts NeuroPace, Inc.
- Sector Chart